NICE guidance (TA664) recommends Saxenda as a treatment option for weight management in adults within specialist weight management services (Tier 3 or 4) who have: A BMI of at least 35 kg/m (or at least 32.5 kg/m in people from certain minority ethnic groups) A BMI of at least 30 kg/m (or at least 27.5 kg/m in people from certain minority ethnic groups) and weight-related comorbidities Treatment should be discontinued if patients do not lose at least 5% of their initial body weight after 12 weeks at the maintenance dose of 3.0 mg
In addition, previous studies have shown that administration of Exendin-4 may increase patients anxiety, which may exacerbate the anxiety of heroin withdrawal patients after medication, making it difficult for them to tolerate this anxiety and give up continuing medication or develop into depression, which may limit the development of GLP-1 analogs [27]
Its dual GLP-1/GIP mechanism can increase metabolic strain
Even with the discount, the $499 price point remains out of reach for many patients
Are we feeling angry, confused, frustrated, exhausted
Given the emerging role of the microbiome in mediating the effects of diet on EEC function, it is essential to explore the direct interactions between gut microbiota and EECs